CA2302838C - Modulation de la voie de signalisation de la sphingosine kinase - Google Patents

Modulation de la voie de signalisation de la sphingosine kinase Download PDF

Info

Publication number
CA2302838C
CA2302838C CA2302838A CA2302838A CA2302838C CA 2302838 C CA2302838 C CA 2302838C CA 2302838 A CA2302838 A CA 2302838A CA 2302838 A CA2302838 A CA 2302838A CA 2302838 C CA2302838 C CA 2302838C
Authority
CA
Canada
Prior art keywords
sphingosine
activity
compound
sphingosine kinase
analyte
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2302838A
Other languages
English (en)
Other versions
CA2302838A1 (fr
Inventor
Mathew Vadas
Jennifer Gamble
Pu Xia
Philip Barter
Kerry-Anne Rye
Brian Wattenberg
Stuart Pitson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Research and Development LLC
Original Assignee
Johnson and Johnson Pharmaceutical Research and Development LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johnson and Johnson Pharmaceutical Research and Development LLC filed Critical Johnson and Johnson Pharmaceutical Research and Development LLC
Publication of CA2302838A1 publication Critical patent/CA2302838A1/fr
Application granted granted Critical
Publication of CA2302838C publication Critical patent/CA2302838C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La présente invention concerne un procédé permettant de moduler l'activité cellulaire et des agents pouvant être utilisés dans ce procédé. Plus particulièrement, la présente invention traite d'un procédé permettant de moduler l'activité des cellules endothéliales et plus particulièrement l'expression des molécules d'adhésion cellulaire. De manière encore plus spécifique, la présente invention a pour objet un procédé permettant de traiter les insuffisances coronariennes en prévenant ou en réduisant l'expression des molécules d'adhésion des cellules endothéliales.
CA2302838A 1997-09-08 1998-09-08 Modulation de la voie de signalisation de la sphingosine kinase Expired - Lifetime CA2302838C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO9002A AUPO900297A0 (en) 1997-09-08 1997-09-08 A method of modulating cellular activity
AUPO9002 1997-09-08
PCT/AU1998/000730 WO1999012533A1 (fr) 1997-09-08 1998-09-08 Procede de modulation de l'activite cellulaire

Publications (2)

Publication Number Publication Date
CA2302838A1 CA2302838A1 (fr) 1999-03-18
CA2302838C true CA2302838C (fr) 2010-03-16

Family

ID=3803288

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2302838A Expired - Lifetime CA2302838C (fr) 1997-09-08 1998-09-08 Modulation de la voie de signalisation de la sphingosine kinase

Country Status (5)

Country Link
EP (1) EP1011654A4 (fr)
JP (1) JP4570246B2 (fr)
AU (2) AUPO900297A0 (fr)
CA (1) CA2302838C (fr)
WO (1) WO1999012533A1 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100798375B1 (ko) * 1999-05-13 2008-01-28 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 스핀고신 키나제 효소
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same
EP1195604A1 (fr) * 2000-09-29 2002-04-10 Warner-Lambert Company Procedés et compositions pour la sondage de modulateurs de lipide kinases
US6610534B2 (en) * 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
EP1404364A4 (fr) * 2001-06-07 2005-09-28 Medvet Science Pty Ltd Sphingosine kinase interagissant avec traf2 et modulant l'activite cellulaire induite par le facteur de necrose tumorale
CA2480661A1 (fr) * 2002-03-28 2003-10-09 Medvet Science Pty. Ltd. Methode de modulation d'activite cellulaire
JP2006514828A (ja) * 2002-10-14 2006-05-18 メドベット・サイエンス・プロプライエタリー・リミテッド スフィンゴシンキナーゼの機能的レベルを調節することによって上皮細胞活性を調節する方法
EP1481680A1 (fr) 2003-05-30 2004-12-01 Aventis Pharma Deutschland GmbH Utilisation de S1P
AU2005253643B2 (en) * 2004-06-15 2011-12-01 Medvet Science Pty. Ltd. Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
MXPA06014888A (es) * 2004-06-15 2007-03-21 Medvet Science Pty Ltd Metodos para modular actividad celular que involucra esfingosina cinasa y agentes para los mismos, y variantes de esfingosina cinasa.
JP2008528450A (ja) * 2005-01-21 2008-07-31 メドベット サイエンス ピーティーワイ． リミティッド 細胞損傷の治療法
US8747844B2 (en) 2010-07-30 2014-06-10 Saint Louis University Methods of treating pain
US10877045B2 (en) 2015-07-21 2020-12-29 Saint Louis University Compositions and methods for diagnosing and treating endometriosis-related infertility

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766111A (en) * 1985-10-31 1988-08-23 Trustees Of Boston University Lipids with plasmin inhibitory properties
WO1988009345A1 (fr) * 1987-05-20 1988-12-01 The Rogosin Institute Particules d'hdl (lipoproteine a haute densite) reconstituee et leurs utilisations
US5190876A (en) * 1988-12-27 1993-03-02 Emory University Method of modifying cellular differentiation and function and compositions therefor
CA2007507C (fr) * 1989-02-03 1998-05-19 Yasuyuki Igarashi Sphingosine et n-methyl-sphingosine inhibiteurs de la croissance des cellules
US5466716A (en) * 1990-12-31 1995-11-14 The Biomembrane Institute Liposomal trimethylsphingosine
EP0710107A4 (fr) * 1993-07-23 1997-05-28 Biomembrane Inst Derives de n,n,n-trimethylsphingosine
AU717243B2 (en) * 1994-12-29 2000-03-23 Regents Of The University Of California, The Compounds for inhibition of ceramide-mediated signal transduction
US5677189A (en) * 1995-06-29 1997-10-14 Oncomembrane, Inc. Method for quantifying sphingosine and for diagnosing platelet activation
JPH09176083A (ja) * 1995-12-28 1997-07-08 Sankyo Co Ltd 新規化合物ｆ−１２５０９ａ

Also Published As

Publication number Publication date
WO1999012533A1 (fr) 1999-03-18
EP1011654A4 (fr) 2004-09-15
JP2001515857A (ja) 2001-09-25
AU757358B2 (en) 2003-02-20
EP1011654A1 (fr) 2000-06-28
AUPO900297A0 (en) 1997-10-02
JP4570246B2 (ja) 2010-10-27
CA2302838A1 (fr) 1999-03-18
AU8965898A (en) 1999-03-29

Similar Documents

Publication Publication Date Title
US6649362B2 (en) Screening method for an agent having an effect on a sphingosine kinase signaling pathway
CA2302838C (fr) Modulation de la voie de signalisation de la sphingosine kinase
US20070071752A1 (en) Sphingosine kinase enzyme
AU2006201939B2 (en) A method of modulating cellular activity
US20050100547A1 (en) Sphingosine kinase interacts with traf2 and modulates tumor necrosis factor-induced cellular activity
AU2003204254B2 (en) A Method of Modulating Cellular Activity
US20080039364A1 (en) Modulating serum amyloid a interaction with tanis and agents useful for same
EP1910524A1 (fr) Modulation de la signalisation de la sphingosine kinase
US20080279897A1 (en) Method of Treating Cellular Damage
US20070265196A1 (en) Method of Modulating Pro-Inflammatory and Inflammatory Activity Mediated by C-Reactive Protein
CA2612773A1 (fr) Modulation de la signalisation de la sphingosine kinase
AU2002344670A1 (en) Modulating serum amyloid A interaction with tanis and agents useful for same
AU2002344670B8 (en) Modulating serum amyloid A interaction with tanis and agents useful for same
AU2006207818A1 (en) A method of treating cellular damage
AU2006261584A1 (en) Modulation of sphingosine kinase signalling
AU2005207081A1 (en) A method of modulating pro-inflammatory and inflammatory activity mediated by C-reactive protein
WO2000002589A1 (fr) Modulation de l'activite des cellules hematopoietiques et agents utilises a cette intention
Xia 2. An isolated polynucleotide according to claim 1, the polynucleotide comprising a sequence at least 95% identical to SEQ ID NO: 1. 3. An isolated polynucleotide sequence that hybridizes to the nucleotide sequence of claim 2 stringency conditions of about 65 C C. and about 50% v/v formamide and about 0.15 M salt. 4. An isolated polynucleotide according to claim 1, the polynucleotide encoding a polypeptide having the sequence of SEQ ID NO: 2. 5. An isolated polynucleotide according to claim 1, the polynucleotide comprising the sequence of SEQ ID NO: 1. 6. An expression system comprising a polynucleotide according to claim 1.
AU2006261583A1 (en) Modulation of sphingosine kinase signalling
WO2004022090A1 (fr) Procede de modulation de l'activite cellulaire endotheliale

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20180910